title: Effects of new quinizarin derivatives on both HCV NS5B RNA polymerase and HIV-1 reverse transcriptase associated ribonuclease H activities.
abstract: Human immunodeficiency virus 1 (HIV-1) and Hepatitis C virus (HCV) affect 60 and 170 million infected individuals worldwide, respectively, and co-infection by both pathogens is often observed. This represents a serious public health problem that requires the identification of new drugs targeting essential phases of the life cycle of these two viruses. In this report, the synthesis and inhibitory activity of quinizarin derivatives towards both HCV NS5B polymerase and HIV-1 reverse transcriptase associated functions are reported. Our results demonstrate that anthraquinone derivatives are promising anti-polymerase viral inhibitors.
authors: Department of Life and Environmental Sciences, University of Cagliari, Monserrato, Italy.
authors: E
authors: E
authors: Tramontano
authors: T
authors: T
authors: Kharlamova
authors: L
authors: L
authors: Zinzula
authors: F
authors: F
authors: Esposito
mesh_terms: D000880:Anthraquinones / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D012321:DNA-Directed RNA Polymerases / Q000037:antagonists & inhibitors / Q000235:genetics; D015195:Drug Design; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors* / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology; D016174:Hepacivirus / Q000187:drug effects* / Q000201:enzymology; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy; D006801:Humans; D020128:Inhibitory Concentration 50; D007364:Intercalating Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology; D012324:RNA-Dependent RNA Polymerase / Q000037:antagonists & inhibitors / Q000235:genetics; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors; D012093:Replicon / Q000187:drug effects; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D054309:Ribonuclease H, Human Immunodeficiency Virus / Q000037:antagonists & inhibitors* / Q000235:genetics; D013329:Structure-Activity Relationship; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000880:Anthraquinones; D019380:Anti-HIV Agents; D007364:Intercalating Agents; D011994:Recombinant Proteins; D018894:Reverse Transcriptase Inhibitors; D017361:Viral Nonstructural Proteins; C034890:1,4-dihydroxyanthraquinone; C514824:reverse transcriptase, Human immunodeficiency virus 1; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase; D054303:HIV Reverse Transcriptase; D012321:DNA-Directed RNA Polymerases; D054309:Ribonuclease H, Human Immunodeficiency Virus